Concepedia

David L. Cutler

DL

Statistics

Publications

79

Citations

4.4K

H-Index

32

Active since

1980

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Athenex (United States)

Pfizer (United States)

Pfizer (France)

Oregon Health & Science University

David L. Cutler is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicine, and clinical pharmacology.

ORCID

Publications per year

1980–2022

79

Publications

79

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

Anthony W. Tolcher, Stanton L. Gerson, Christiane Geyer et al. · British Journal of Cancer · 2003 · 369 citations · Full text

, , +16

SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 Nonresponders

Christoph Sarrazin, Frank Wagner, Nicole Forestier et al. · Gastroenterology · 2007 · 311 citations

, , +14

A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.

Alex A. Adjei, Charles Erlichman, J. Nathan Davis et al. · PubMed · 2000 · 243 citations

, , +10

Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.

Sharyn D. Baker, Mark Wirth, Paul Statkevich et al. · PubMed · 1999 · 225 citations

, , +16

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

M. Brada, Ian Judson, Philip Beale et al. · British Journal of Cancer · 1999 · 208 citations · Full text

, , +17

1–5 of 79